{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bacteremia+Due+to+Staphylococcus+Aureus",
    "query": {
      "condition": "Bacteremia Due to Staphylococcus Aureus"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 21,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bacteremia+Due+to+Staphylococcus+Aureus&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T06:48:49.661Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04775953",
      "title": "DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Staphylococcal Bacteraemia"
      ],
      "interventions": [
        {
          "name": "Cefazolin",
          "type": "DRUG"
        },
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Daptomycin",
          "type": "DRUG"
        },
        {
          "name": "Nafcillin",
          "type": "DRUG"
        },
        {
          "name": "Oxacillin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 200,
      "start_date": "2021-04-22",
      "completion_date": "2023-12-01",
      "has_results": true,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-05-22T06:48:49.661Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Torrance, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04775953"
    },
    {
      "nct_id": "NCT02208063",
      "title": "A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bacteremia"
      ],
      "interventions": [
        {
          "name": "Telavancin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        },
        {
          "name": "Daptomycin",
          "type": "DRUG"
        },
        {
          "name": "Synthetic penicillin",
          "type": "DRUG"
        },
        {
          "name": "Cefazolin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2014-12",
      "completion_date": "2018-04-12",
      "has_results": true,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-05-22T06:48:49.661Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02208063"
    },
    {
      "nct_id": "NCT02357966",
      "title": "Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Staphylococcus Aureus Bacteremia"
      ],
      "interventions": [
        {
          "name": "514G3 (2 mg/kg) plus standard IV antibiotic treatment",
          "type": "BIOLOGICAL"
        },
        {
          "name": "514G3 (10 mg/kg) plus standard IV antibiotic treatment",
          "type": "BIOLOGICAL"
        },
        {
          "name": "514G3 (40 mg/kg) plus standard IV antibiotic treatment",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo plus standard IV antibiotic treatment",
          "type": "OTHER"
        },
        {
          "name": "514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo plus standard IV antibiotic treatment: Phase II",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "XBiotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2015-05",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-05-22T06:48:49.661Z",
      "location_count": 2,
      "location_summary": "Columbus, Georgia • Charlotte, North Carolina",
      "locations": [
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02357966"
    },
    {
      "nct_id": "NCT03138733",
      "title": "Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Staphylococcus Aureus Bacteremia"
      ],
      "interventions": [
        {
          "name": "Ceftobiprole medocaril",
          "type": "DRUG"
        },
        {
          "name": "Daptomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Basilea Pharmaceutica",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 390,
      "start_date": "2018-08-26",
      "completion_date": "2022-03-11",
      "has_results": true,
      "last_update_posted_date": "2023-11-08",
      "last_synced_at": "2026-05-22T06:48:49.661Z",
      "location_count": 5,
      "location_summary": "Chula Vista, California • West Palm Beach, Florida • Butte, Montana + 2 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Butte",
          "state": "Montana"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03138733"
    },
    {
      "nct_id": "NCT07148960",
      "title": "Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Staphylococcus Aureus Bacteremia"
      ],
      "interventions": [
        {
          "name": "Early Dual IV Antibiotic Therapy - MRSA",
          "type": "DRUG"
        },
        {
          "name": "Early Dual IV Antibiotic Therapy - MSSA",
          "type": "DRUG"
        },
        {
          "name": "Single Agent IV Antibiotic Therapy - MRSA",
          "type": "DRUG"
        },
        {
          "name": "Single Agent IV Antibiotic Therapy - MSSA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "West Virginia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2025-09-15",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-05-22T06:48:49.661Z",
      "location_count": 1,
      "location_summary": "Morgantown, West Virginia",
      "locations": [
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07148960"
    },
    {
      "nct_id": "NCT05329168",
      "title": "ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bacteremia Due to Staphylococcus Aureus",
        "Left Sided Infective Endocarditis (Disorder)",
        "Right Sided Infective Endocarditis (Disorder)",
        "Endocarditis Infective"
      ],
      "interventions": [
        {
          "name": "Tonabacase (LSVT-1701)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lysovant",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-05-01",
      "completion_date": "2023-11-01",
      "has_results": false,
      "last_update_posted_date": "2022-06-30",
      "last_synced_at": "2026-05-22T06:48:49.661Z",
      "location_count": 1,
      "location_summary": "Butte, Montana",
      "locations": [
        {
          "city": "Butte",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05329168"
    },
    {
      "nct_id": "NCT00319826",
      "title": "Virulence Determinants in S Aureus Bacteremia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bacteremia"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1354,
      "start_date": "2004-03",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2016-04-28",
      "last_synced_at": "2026-05-22T06:48:49.661Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00319826"
    },
    {
      "nct_id": "NCT05184764",
      "title": "Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bacteremia",
        "Staphylococcus Aureus",
        "Staphylococcus Aureus Bacteremia",
        "Bacteremia Staph",
        "Bacteremia Due to Staphylococcus Aureus"
      ],
      "interventions": [
        {
          "name": "AP-SA02",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Armata Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2022-04-26",
      "completion_date": "2025-01-14",
      "has_results": true,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-05-22T06:48:49.661Z",
      "location_count": 23,
      "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05184764"
    },
    {
      "nct_id": "NCT00062647",
      "title": "Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gram-Positive Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "Telavancin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin, nafcillin, oxacillin, or cloxacillin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2003-08",
      "completion_date": "2006-08",
      "has_results": true,
      "last_update_posted_date": "2019-01-16",
      "last_synced_at": "2026-05-22T06:48:49.661Z",
      "location_count": 1,
      "location_summary": "Marietta, Georgia",
      "locations": [
        {
          "city": "Marietta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00062647"
    },
    {
      "nct_id": "NCT03162250",
      "title": "Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bacteremia"
      ],
      "interventions": [
        {
          "name": "DSTA4637S",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SOC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 27,
      "start_date": "2017-07-13",
      "completion_date": "2020-01-15",
      "has_results": false,
      "last_update_posted_date": "2020-01-22",
      "last_synced_at": "2026-05-22T06:48:49.661Z",
      "location_count": 4,
      "location_summary": "Torrance, California • Detroit, Michigan • Royal Oak, Michigan + 1 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03162250"
    }
  ]
}